8-K: Vaxart Secures Nasdaq Listing Extension with Conditions

Vaxart, Inc. received an extension from Nasdaq to regain compliance with the minimum bid price requirement, contingent on a reverse stock split and shareholder approval.

Summary

• The Nasdaq Hearings Panel granted Vaxart's request to continue its listing on Nasdaq, subject to specific conditions.
• Vaxart must obtain shareholder approval for a reverse stock split (RSS) on or before September 5, 2025.
• The company is required to complete the RSS on or before October 6, 2025.
• Vaxart must demonstrate compliance with Nasdaq's minimum bid price requirement ($1.00 per share) on or before October 17, 2025.
• Failure to obtain shareholder approval for the RSS by September 5, 2025, will result in the delisting of the company's securities.
• The company previously received a delisting notification on July 1, 2025, due to its common stock falling below the $1.00 minimum bid price for 30 consecutive business days.

Sentiment

Score: 6

Explanation: The decision to grant an extension is a positive step, averting immediate delisting. However, the company still faces significant hurdles, including securing shareholder approval for a reverse stock split and demonstrating sustained compliance, indicating ongoing risk and uncertainty.

Positives

• The Nasdaq Hearings Panel granted Vaxart's request for continued listing, providing a clear path to avoid immediate delisting.
• The company has a defined set of conditions and deadlines to regain compliance with Nasdaq's listing rules.
• Management is actively engaging with stockholders, including through a virtual fireside chat, to secure support for the reverse stock split proposal.

Negatives

• Vaxart remains non-compliant with Nasdaq's minimum bid price requirement, indicating ongoing operational or market challenges.
• Continued listing is contingent on shareholder approval and the successful completion of a reverse stock split, which introduces execution risk.
• Failure to meet the September 5, 2025, deadline for shareholder approval of the RSS will result in immediate delisting.
• The Nasdaq Listing and Hearing Review Council reserves the right to review and potentially modify or reverse the Panel's decision.

Risks

• Failure to obtain shareholder approval for the reverse stock split by September 5, 2025, will lead to the delisting of the company's securities.
• Failure to complete the reverse stock split by October 6, 2025, or demonstrate compliance with the minimum bid price requirement by October 17, 2025, will result in delisting.
• The Nasdaq Listing and Hearing Review Council may, on its own motion, review the Panel's decision within 45 calendar days, potentially affirming, modifying, reversing, dismissing, or remanding it.
• The company operates in a 'challenging environment for vaccine companies,' which could impact its ability to maintain compliance and achieve future success.
• General risks and uncertainties described under Item 1A Risk Factors in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company's future on Nasdaq is contingent on successfully executing a reverse stock split and regaining compliance with the minimum bid price requirement by October 17, 2025. Management believes maintaining the Nasdaq listing is crucial for the company's future success.

Management Comments

• "We appreciate Nasdaq for recognizing our continued efforts to regain compliance and granting us an extension."
• "In this challenging environment for vaccine companies, our Nasdaq listing is crucial for our future success, and this positive outcome hinges on a successful reverse stock split."
• "We have spoken to many of our stockholders and now it is up to them to vote to secure our future on Nasdaq. We hope we can count on their support."

Industry Context

The CEO's comment about a 'challenging environment for vaccine companies' suggests broader industry headwinds that may be contributing to Vaxart's stock performance and the necessity of a reverse stock split to maintain its listing.

Stakeholder Impact

• Shareholders: Must vote on the reverse stock split; failure to approve could lead to delisting and a significant loss of liquidity. A reverse stock split will reduce the number of outstanding shares and increase the per-share price, which is necessary to maintain the Nasdaq listing.
• Employees: Continued Nasdaq listing can provide stability and access to capital, indirectly benefiting employees. Delisting could negatively impact employee morale and retention.
• Investors/Analysts: The decision provides clarity on the company's immediate future regarding its listing status but highlights ongoing challenges and the need for successful execution of the compliance plan.

Next Steps

• Obtain shareholder approval for a reverse stock split by September 5, 2025.
• Complete the reverse stock split by October 6, 2025.
• Demonstrate compliance with Nasdaq's minimum bid price requirement by October 17, 2025.
• Continue direct engagement with stockholders to address questions and secure support for the reverse stock split proposal.

Key Dates

Recommendation

The company has received a crucial extension to maintain its Nasdaq listing, which is a positive development that prevents immediate delisting. However, this is contingent on successfully executing a reverse stock split, which requires shareholder approval and carries execution risk. While the immediate threat of delisting has been mitigated, the underlying issue of the low share price and the need for a reverse stock split indicate ongoing challenges. Investors should hold to see if the company successfully navigates these conditions and demonstrates sustained compliance, as failure to do so would lead to delisting and significant negative impact.

Keywords

Vaxart, VXRT, Nasdaq, Delisting, Reverse Stock Split, Minimum Bid Price, Biotechnology, Vaccine Company, SEC Filing, 8-K